Lilly Signs $2.75B AI Drug Discovery Deal With Insilico

Insilico Medicine and Eli Lilly have entered a multi-program AI-driven drug discovery collaboration, combining Insilico’s generative modeling platforms with Lilly’s clinical and commercialization infrastructure. Under the agreement, Insilico receives $115 million upfront, with potential milestone payments bringing the total deal value to approximately $2.75 billion, in addition to tiered royalties on future product sales.